Acute arterial thrombosis causes endothelial dysfunction: A new paradigm for thrombolytic therapy  by Kashyap, Vikram S. et al.
thrombosis alters endothelial function, as evidenced by a
decreased ability for the vessel wall to relax after appro-
priate stimulation.3,4 We postulate that this may be
caused by decreased nitric oxide (NO) function. This
phenomena may have significant clinical implications in
the treatment of arterial thrombosis. Specifically, some
clinical scenarios in which protecting endothelial func-
tion and vasomotor tone may be important include
patients with vasospasm or early rethrombosis after
peripheral intervention and patients with distal revascu-
larization and poor arterial flow. Our hypothesis was that
thrombus-mediated endothelial dysfunction is not
caused by endothelial cell loss, but by decreased NO. In
this study, we planned to answer these questions: (1)
What is the time course of alteration of endothelial func-
tion after acute thrombosis? (2) What is the cause of
these effects? and (3) Will supplementing standard
thrombolytic therapy with the NO precursor, L-arginine,
have any effect on endothelial function?
Acute arterial thrombosis remains an area of intense
clinical and laboratory interest in vascular surgery. Many
innovations in the clinical arena for the treatment of arte-
rial thrombosis have recently been obtained, mostly in
optimizing thrombolytic therapy.1,2 However, the physi-
ologic responses of the arterial wall to acute thrombosis
have received less attention. We have observed that acute
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Purpose: The goals of this study were to delineate the time course of endothelial dysfunction after arterial thrombosis,
to determine the cause of endothelial dysfunction in this setting, and to determine whether modulating standard
thrombolytic therapy would ameliorate the thrombosis-mediated endothelial dysfunction.
Methods: Male adult rats underwent infrarenal aortic occlusion by means of clip ligature to induce arterial thrombosis.
After 30 minutes, 1, 2, and 3 hours, ring segments from the infrarenal aorta were harvested and placed into physio-
logic buffer baths. With the use of a force transducer, both endothelial-dependent relaxation (EDR) and endothelial-
independent relaxation (EIR) were measured. Endothelial function and presence were determined by means of factor
VIII immunohistochemical staining. Endothelial morphology was evaluated with scanning electron microscopy (SEM).
Nitric oxide (NO) levels were determined with a chemiluminescent assay of its nitrite/nitrate metabolites (NOx).
Standard thrombolytic therapy with urokinase (UK) was infused into thrombosed aortic ring segments and compared
with UK supplemented with both low-dose L-arginine (2 mmol) and high-dose L-arginine (20 mmol).
Results: Arterial thrombosis decreases EDR. The nadir of EDR occurs 1 hour after thrombosis (mean ± SE, 13% ± 6.4%
vs 94% ± 2.6% for controls, P < .005), with persistent lowering of EDR as long as 3 hours after thrombosis. EIR is
preserved, and vasoconstriction with norepinephrine or potassium buffer is unaltered. Both endothelial function and
presence (n = 6 per group) were documented by means of factor VIII immunohistochemistry. An intact monolayer of
endothelium at all time intervals after thrombosis was revealed by means of SEM analysis. No differences between con-
trol and thrombosed specimens were revealed by means of the grading of SEM images. Local NOx levels were lower
after 1 hour of thrombosis, with an increase higher than baseline values at 3 hours. The addition of low-dose L-argi-
nine resulted in a minor increase in EDR. However, high-dose L-arginine resulted in a significant increase in EDR ver-
sus controls receiving UK alone (64% ± 6.3% vs 38% ± 4.4%, P < .05). Correspondingly, local NOx levels were 20-fold
higher after the high-dose L-arginine supplementation when compared with UK thrombolysis alone (2.8 ± 0.52
µmol/L vs 0.133 ± 0.02 µmol/L, n = 6 samples/group, P < .005).
Conclusion: Acute arterial thrombosis causes endothelial dysfunction, without causing endothelial cell loss. Endothelial
function reaches a nadir after 1 hour of thrombosis. EIR and vasoconstriction remain unaffected, indicating normal
smooth muscle cell function. NOx levels suggest that NO levels are decreased acutely after thrombosis. Supplementing
standard thrombolytic therapy with the NO precursor, L-arginine, ameliorates the endothelial dysfunction seen after
acute thrombosis by increasing local NO production. (J Vasc Surg 2001;34:323-9.)
MATERIALS AND METHODS
Animals and surgical procedures. Adult male
Sprague-Dawley rats weighing 350 to 500 mg were used
for all experiments. All animals were handled and cared for
under institutional guidelines in compliance with the
Guide for the Care and Use of Laboratory Animals
(Institute of Laboratory Animal Resources, National
Research Council. Washington: National Academy Press;
1996). Intramuscular injections of ketamine (100 mg/kg)
and acepromazine (5 mg/kg) were used for anesthesia.
The aorta was ligated with small surgical clips just distal to
the renal arteries and proximal to the bifurcation to induce
arterial thrombosis. A handheld continuous-wave Doppler
probe was used as a means of confirming the lack of blood
flow through the occluded segment. Aortic segments were
harvested before any intervention (controls), after a pre-
scribed interval of thrombosis, or after thrombosis and
infusion of thrombolytic therapy. The presence of intralu-
minal thrombus or dissolution of thrombus was confirmed
in all animals at the time of tissue harvest.
Studies involving infusion of thrombolytic therapy were
performed after 1 hour of thrombosis. Urokinase (UK;
Abbott Laboratories, Chicago, Ill) at a concentration of
5000 U/mL was infused into the infrarenal aorta through
a 25-gauge needle attached to an infusion pump (Harvard
Apparatus, Holliston, Mass) for a period of 30 minutes at
0.2 mL/min (1000 U/min) before aortic harvest and
blood sampling. As the infusion was initiated, the distal clip
was removed from the aorta. In studies with L-arginine
(Sigma Chemicals, St Louis, Mo), it was dissolved into the
UK to give a final concentration of 2 mmol/L (low dose)
or 20 mmol/L (high dose). The L-arginine doses were cho-
sen from reports that were published earlier.5,6
Studies of endothelial and smooth muscle cell func-
tion. The infrarenal rodent aorta was carefully harvested,
placed in Krebs-Hensleit physiologic solution (NaCl, 118
mmol/L; NaHCO3, 25 mmol/L; glucose, 5.6 mmol/L;
KH2PO4, 1.2 mmol/L; KCl, 4.7 mmol/L; MgSO4, 1.2
mmol/L; CaCl2, 1.5 mmol/L) and sectioned into 4-mm
segments. The segments were mounted on standard tung-
sten wire triangles (A-M Systems, Everett, Wash), attached
to isometric force displacement transducers (FTO3C,
Grass Instrument, Quincy, Mass), and placed into tissue
baths.7 The tissue baths were temperature controlled with
a heated water jacket at 37°C. Standard Krebs-Hensleit
solution was used with a 95% oxygen–5% carbon dioxide
gas mixture bubbled into the baths.
Preload (2 grams) was applied to the arterial rings, and
the vessels were allowed to equilibrate for 1 hour. After
equilibration, the arteries were constricted with a high
potassium solution (standard Krebs, except KCl, 122
mmol/L) and allowed to reequilibrate. This represented
the maximal contractile force for the artery (F-max). The
baths were then emptied and rinsed three times with the
Krebs solution and again allowed to equilibrate. After
reequilibration, the arteries were constricted to 75% of F-
max with 10–5 mol/L norepinephrine (NE; Sigma).
Acetylcholine (Ach; Sigma) was then added in incremen-
tal log concentrations from 10–9 mol/L to 10–4 mol/L
for the determination of endothelial-dependent relaxation
(EDR). EDR was also measured with the reagent
bradykinin in initial studies. Bradykinin-derived EDR con-
firmed endothelial response and correlated with the Ach-
derived EDR. Endothelial-independent relaxation (EIR)
was measured in a similar fashion with sodium nitroprus-
side (NTP; Sigma) from 10–7 to 10–5 mol/L. Baths were
rinsed, and arterial segments were brought to 75% F-max
with NE between each reagent.
Evaluation of endothelial morphology. For light
microscopy and factor VIII immunohistochemistry, aortic
ring samples were harvested, rinsed, and immediately
placed into 10% neutral buffered formalin. Formalin-fixed
paraffin-embedded blocks were sectioned at 4 µm and
prepared as described earlier.8 Immunostaining was per-
formed on a DAKO Autostainer (Dako, Carpenteria,
Calif) with the Envision+ (rabbit, peroxidase) detection
system (Dako). For factor VIII immunohistochemistry,
slides were incubated in primary antibody (Rabbit anti-
von Willebrand factor, Dako) diluted to 1-to-1000 for 30
minutes, rinsed in phosphate-buffered saline, and then
incubated in the Envision+ (antirabbit) for 30 minutes.
The antibody was then localized with diaminobenzidine as
the chromogen and counterstained with Harris hema-
toxylin.8 Negative control slides received normal rabbit
immunoglobulin fraction (Dako) in place of the primary
antibody. Rat uterine and muscle tissues were used for the
positive control. This method was both sensitive and spe-
cific for rat endothelium. However, separate sections were
used for attempts at locating CD34, but excessive cross-
reactivity precluded with the anti-CD34 antibody.
For scanning electron microscopy (SEM), the aortic
tissue ring segment was incised to allow en face imaging.
This rectangular segment of tissue was immediately placed
into 2% glutaraldehyde and fixed overnight. The specimens
were rinsed in phosphate-buffered saline three times and
then dehydrated in a graded series of ethanol (30%-100%).
Then, the samples were treated with a graded series of
hexamethyldisilazane, air dried, and gold sputter coated
before imaging (Cambridge 360 SEM microscope).
Analysis of nitric oxide metabolites. The determina-
tion of NO with a chemiluminescent analysis has been
described in detail.9 In brief, for systemic determination of
NO, samples of venous blood were taken from the rat infe-
rior vena cava at the end of the interval of thrombosis or
after thrombolytic infusion. Samples were centrifuged at
3600 rpm, yielding plasma that was aliquoted and placed at
4°C. For the local determination of NO, aortic ring sam-
ples were suspended in physiologic Krebs buffer for 5 min-
utes after thrombosis or thrombosis/thrombolysis. One
milliliter of the buffer was drawn, refrigerated, and assayed.
All samples were run in duplicate. The NO concentration
was determined by reconverting its oxidation end products
nitrite (NO2–) and nitrate (NO3). This was followed by
measurement in a chemiluminescence detector (NOx ana-
lyzer, Model 2108, Dosibi Environmental, Glendale,
Calif).9 The detector’s range is accurate from picomoles to
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molar concentrations. The instrument underwent calibra-
tion with known NOx values and blank samples on a rou-
tine basis.
RESULTS
The effect of arterial thrombosis on endothelial func-
tion was measured. After specific intervals of rat aortic
thrombosis, both EDR and EIR were measured. As seen
in Fig 1, nonthrombosed control rat aortic EDR increased
with increasing Ach doses to 94% ± 3% (± SE) of maximal
EDR. However, after 30 minutes of arterial thrombosis,
EDR was depressed to 48% ± 7% at the highest Ach dose
of 10–4. EDR was further depressed and reached a nadir
after 1 hour of thrombosis (13% ± 6%). EDR improved at
the 2- and 3-hour thrombosis intervals, but still remained
markedly depressed compared with that of the nonthrom-
bosed controls, with approximately a 50% reduction in
EDR (P < .005, analysis of variance). EIR was measured
by means of response to log escalating doses of NTP. The
arterial ring segments responded uniformly to NTP, with
a 100% EIR at the 10–6 and 10–5 doses of NTP. All arte-
rial ring segments constricted similarly with norepineph-
rine and high-potassium Krebs buffer.
Histologic sections of rat aortic tissue were examined
by means of both immunohistochemistry with factor VIII
staining and SEM to test the hypothesis of whether the
changes in endothelial function could be caused by
endothelial cell loss. The intima was revealed to be pre-
served by means of factor VIII staining of the normal rat
aorta after 1 hour of thrombosis and 3 hours of thrombo-
sis (Fig 2). There was no evidence of endothelial cell loss;
endothelium was detected by means of factor VIII stain-
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ing in all the slides examined (n = 6 per group). To further
investigate this, we used SEM as a means of examining the
morphology of the lumen of the aortic ring specimens.
SEM images from the groups (n = 6 per group) were
graded by blinded observers. When compared with nor-
mal rat aortic tissue, there was no difference in endothelial
morphology, and no areas of denudation or endothelial
cell loss were seen. Both the 1-hour and 3-hour arterial
thrombosis groups had confluent monolayers of endothe-
lium similar to that of control vessels (Fig 3).
Systemic levels of the metabolites of NO, NOx, were
measured with a chemiluminescent assay to test the
hypothesis that the changes in EDR were related to
changes in NO function. The systemic NOx levels mir-
rored the changes in EDR. NOx levels in control animals
were 39.2 ± 10 µmol/L and decreased to 36.5 ± 6.2
µmol/L after 1 hour of thrombosis. This was followed by
Fig 1. EDR plotted as percent relaxation of baseline, with log increases in the dose of acetylcholine (Ach). EDR of nonthrombosed rat
aortic ring samples is compared with that of aortic samples after thrombosis of different intervals. EDR is depressed in all thrombosis
groups, reaching a nadir after 1 hour of thrombosis (13% ± 6%). There is some recovery of EDR after 1 hour of thrombosis, but EDR
is still approximately 50% of control values. n = 7 to 9 per group. *P < .005, analysis of variance.
Fig 2. Factor VIII immunohistochemistry of rat aorta.
Endothelium is represented by the dark-staining monolayer of
cells (white arrows). Functional endothelium was present in nor-
mal control aortic specimens (C) and in aortic specimens that had
been subjected to thrombosis for 1 hour (1 hr) and 3 hours (3 hr).
Original magnification, 200×.
a rebound to 38.9 ± 1.5 µmol/L at 3 hours of thrombo-
sis (n = 6 samples/group, P = not significant, analysis of
variance). Local levels of NOx reflected NO production at
the level of the arterial wall (Fig 4). Control levels were
1.05 ± 0.34 µmol/L, decreased to 0.38 ± 0.17 µmol/L at
1 hour of thrombosis, and then rebounded higher than
baseline levels to 1.5 ± 1.3 µmol/L at 3 hours of arterial
thrombosis (n = 6 samples/group, P < .05 for controls vs
thrombus 1-hour group, t test).
Our next focus was to test whether increasing the
available substrate for NO production would ameliorate
the endothelial dysfunction caused by thrombus. After 1
hour of arterial thrombosis, UK thrombolytic therapy was
compared with UK supplemented with L-arginine. All ani-
mals had complete dissolution of aortic thrombus after a
30-minute infusion of UK. As seen in Fig 5, UK infusion
and clearing of the thrombus resulted in an EDR of 38%
± 4% at the 10–4 mol/L Ach dose. EDR of arterial ring
samples after 1 hour of thrombosis alone was 13% ± 6%, as
seen in Fig 1. Adding a low concentration of L-arginine (2
mmol/L) to UK thrombolytic therapy resulted in a minor
increase in EDR, to 41% ± 7%. However, adding a high
concentration of L-arginine (20 mmol/L) to the UK
resulted in a significant increase in EDR, with a peak of
64% ± 6% (n = 8 to 10 samples/group, P < .05, analysis of
variance). EIR approached 100% and showed no signifi-
cant difference among the three groups tested.
Systemic NOx levels after thrombolysis showed a trend
of higher levels of NOx with increasing L-arginine supple-
mentation. The systemic NOx levels for the UK group
were 25.0 ± 2.5 µmol/L, increased to 26.3 ± 1.4 µmol/L
with low-dose L-arginine supplementation, and increased
to 27.9 ± 3.7 µmol/L with the high-dose L-arginine (P =
not significant). The measurement of local NOx levels
showed more dramatic differences (Fig 6). The local NOx
levels for the UK group were 0.133 ± 0.02 µmol/L and
increased to 0.3 ± 0.11 µmol/L with low-dose L-arginine
supplementation. However, L-arginine supplementation at
a concentration of 20 mmol/L lead to local NOx levels of
2.8 ± 0.52 µmol/L, a 20-fold increase compared with that
in the UK group (n = 6 samples/group, P < .005, analy-
sis of variance).
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Fig 3. Sample scanning electron microscopy images from rat aortic rings. a, Luminal surface of normal rat aorta revealing confluent
monolayer of endothelial cells (controls). b, Rat aortic luminal surface after 1 hour of thrombosis. Note confluent endothelium with
minimal fibrin debris. c, Rat aortic luminal surface after 3 hours of thrombosis. Confluent monolayer of endothelium is still present, with
some mild fibrin debris and platelets. d, Specimen in which intima has been purposefully rubbed, revealing complete endothelial denuda-
tion. e, Specimen in which endothelial denudation is present (top of image), and vessel wall fracture reveals exposure of subendothelial
matrix (bottom of image). Images d and e are for comparison only and do not represent any of the experimental groups tested. (Bar in
image a indicates 50 µm.)
Fig 4. Local NOx levels significantly decrease after 1 hour of
thrombosis and then increase after 3 hours of thrombosis, reach-
ing levels higher than control animals. n = 6 samples/group. *P
< .05 for controls versus thrombus 1-hour group, t test. 
DISCUSSION
A major problem in vascular surgery is the acute
ischemic insult caused by the occlusion of a vessel by
obstructing thrombus. Despite multiple clinical advances
in the treatment of arterial thrombosis, treatment of this
condition can still be associated with tremendous morbid-
ity and mortality. Common clinical strategies in dealing
with arterial thrombosis include balloon catheter throm-
boembolectomy, which was first introduced in 1963.10
Recently, arterial thrombosis treatment has evolved with
systemic and regional thrombolysis.1,2 However, despite
these advances, there remains very little data on the acute
effects of arterial thrombosis on endothelial function.
The seminal observation that endothelium is a key
mediator of vascular vasomotor reactivity was made in
1980 by Furchgott and Zawadzki.11 The ability of the
artery to relax was attributed to the elusive substance EDR
factor, which was identified as NO by Ignarro and
Moncada.12,13 The process of NO-endothelial interaction
can be quantitatively assessed in the laboratory, and the
measurement of EDR of an artery reflects endothelial
function. Earlier studies of endothelial function in vitro
have been performed, many of them before the elucida-
tion of the NO pathway. Various components of thrombus
have been shown to alter endothelial cell morphology and
function.14,15 However, none of these studies directly
looked at NO presence or function.
Earlier studies of the effects of thrombus on endothe-
lium in vivo have yielded conflicting results. In one study,
thrombosis in arterialized vein grafts was shown to
decrease endothelial metabolism of prostacyclin, suggest-
ing decreased endothelial function from exposure to
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thrombus.16 Thrombus was also shown to induce changes
in endothelial cell morphology, indicating damage to the
endothelium; however, these changes in endothelial mor-
phology were seen after 7 days of thrombosis. In contrast,
a recent study comparing the effects of thrombectomy and
thrombolysis on endothelial function showed no signifi-
cant differences in EDR after exposure to thrombus for 24
hours.17 Furthermore, there appeared to be no morpho-
logic changes in the endothelium exposed to thrombus.
Finally, another similar study comparing balloon
thrombectomy with thrombolysis also revealed no major
changes in the arterial wall architecture of endothelium
exposed to thrombus after 24 hours.18
Fig 5. EDR was measured after 1 hour of thrombosis and thrombolytic infusion. Urokinase (UK) supplemented with 20 mmol/L of
L-arginine (hi L-arg) resulted in significantly higher EDR than UK alone or UK supplemented with 2 mmol/L of L-arginine (lo L-arg).
n = 8 to 10 samples/group. *P < .05, analysis of variance. Ach, Acetylcholine.
Fig 6. Local NOx levels increase after infusion of increasing L-
arginine concentrations in thrombolytic regimen. Urokinase
(UK) supplemented with 20 mmol/L of L-arginine (hi L-arg)
results in 20-fold increase in local NOx levels (2.8 ± 0.52 µmol/L
vs 0.133 ± 0.02 µmol/L. n = 6 samples/group. *P < .005, analy-
sis of variance. lo L-arg, 2 mmol/L of L-arginine.
This study includes two separate experiments. The first
studied the effects of acute arterial thrombosis on
endothelial function. This was initiated because of the
observation made in this laboratory of decreased endothe-
lial function after acute thrombosis in both rat carotid and
rabbit iliac vessels.3,4 This endothelial dysfunction after
thrombosis was independent of ischemia to the occluded
segment and was caused by the presence of intraluminal
thrombus.4 We pursued these observations by looking at
the time course of effects on endothelial function. As
shown in Fig 1, all intervals of arterial thrombosis studied
showed decreased EDR. However, EDR reached a nadir
after 1 hour of thrombosis, with some recovery of
endothelial function afterward. In our earlier reports,
decreased EDR was seen as long as 4 hours after throm-
bosis. The next question we sought to answer was whether
these changes in decreased EDR were caused by endothe-
lial loss. Both with immunohistochemical analysis of factor
VIII and with SEM, no evidence of endothelial loss was
seen. Thus, these changes in EDR were not caused by
decreased endothelial cell mass leading to decreased NO
production. Because the periods of thrombosis are acute,
we doubted that a significant impact on NO production
could occur through a molecular mechanism. Specifically,
between 30 minutes and 3 hours of arterial thrombosis
could be too early to implicate decreased messenger RNA
for NO synthase as a mechanism for the observed changes.
This is a subject of current investigation. However, in this
period, scavenging of NO or decreased production of NO
through other mechanisms could be occurring. NO resis-
tance at the level of the arterial smooth muscle is unlikely
because of the uniform constriction seen in all samples and
the uniform relaxation obtained with NTP in the EIR
studies.
Another possibility that needs further investigation is
that an endogenous constrictor (ie, endothelin-1) could
be augmented in the setting of thrombosis. Decreased
shear stress has been shown to decrease endothelial pro-
duction of NO, and that may account for a portion of the
findings in this study.19 Local NOx levels significantly
decreased at the 1-hour thrombus interval and rebounded
at the 3-hour interval to higher than the baseline level seen
in controls. These changes may indicate that the endothe-
lium is initially stunned after thrombosis and then com-
pensates with increased NO production after 1 hour.
However, despite the increased NO levels at 3 hours of
thrombosis, this did not translate to a normalizing of
EDR, which may indicate that NO changes are only par-
tially responsible for the endothelial dysfunction.
Our second experiment focused on whether adding the
NO precursor, L-arginine, to standard thrombolytic ther-
apy with UK would ameliorate the changes in endothelial
function seen in the first experiment. When a low dose of
L-arginine (2 mmol/L) was added to UK, a minor increase
in EDR was detected. However, adding a high dose of L-
arginine (20 mmol/L) increased EDR significantly, and we
think it ameliorated endothelial dysfunction. Systemic lev-
els of the NO metabolites increased slightly with increasing
L-arginine supplementation. However, local determination
of NOx after thrombolysis revealed a 20-fold increase with
the higher L-arginine concentration.
There was a discrepancy seen with the systemic levels
of NOx between the first and second experiments. We
think that this was caused by the dilution of the blood vol-
ume that occurs with this small animal model during the
thrombolysis experiments. The thrombolytic regimen we
used required a total infusion of 6 mL in the rodent
model. The use of a larger animal model may resolve this
discrepancy.
Other studies support the use of L-arginine to amelio-
rate endothelial dysfunction. In a study by Yao et al,5 L-
arginine was used in a model of coronary thrombosis.
Continuous intracoronary infusion of L-arginine at a con-
centration of 100 µg/kg per minute delayed coronary
thrombosis, hastened thrombolysis, and reduced rethrom-
bosis. The group concluded that L-arginine may delay
intracoronary thrombus formation by inhibiting platelet
aggregation through the increased concentrations of NO.
In another study looking at cardiac function, the addition
of L-arginine to cardioplegia was found to improve con-
tractile recovery and endothelial function.6
Another area of great interest has been the inhibition
of atherogenesis and intimal hyperplasia by L-arginine.
Wang et al20 studied the effects of long-term L-arginine
supplementation in the diets of hypercholesterolemic rab-
bits. They found that L-arginine dietary supplementation
led to decreased coronary atheroma in these animals.
Tarry and Makhoul21 studied the effects of L-arginine on
intimal hyperplasia after balloon angioplasty. Four weeks
after iliac artery angioplasty, the rabbits on an L-argi-
nine–supplemented diet had significantly greater EDR and
reduced intimal thickening on morphometric analysis.
Finally, a recent study evaluated the inhibition of balloon
angioplasty restenosis with local intramural delivery of L-
arginine.22 In the short term after L-arginine infusion,
EDR and local production of nitrogen oxides were
enhanced after iliac artery balloon angioplasty. Even after
a single local administration of L-arginine, NO production
was enhanced for as long as 1 week, and intimal thicken-
ing was reduced when assessed 4 weeks later. Taken
together, the aforementioned studies indicate that aug-
menting NO with L-arginine supplementation at the
endothelial level can have beneficial effects by increasing
vessel diameter, decreasing platelet aggregation, and
inhibiting smooth muscle cell proliferation. Targeted NO
augmentation could be an attractive clinical adjunct,
because of the possibility of increased patency after surgi-
cal and endovascular intervention.
In summation, this study documents that arterial
thrombosis induces endothelial dysfunction without
endothelial damage or cell loss. Also, the data suggest that
altered NO function is the cause of the decreased EDR.
We believe supplementing standard thrombolytic therapy
with the NO precursor, L-arginine, may prove to be an
attractive therapeutic alternative in the treatment of acute
arterial thrombosis.
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